GLP-1s in Cardiovascular-Kidney-Metabolic Syndrome: Going Beyond Weight Loss and Glycemic Control
 

Rachel Allen

Speaker Information

Rachel Bassett Allen, PharmD, CPP, BCACP

Clinical Pharmacist 

Duke University Hospital

Learning Objectives: 

  • Define cardiovascular-kidney-metabolic (CKM) syndrome, including risk factors and staging criteria
  • Describe guideline-directed management strategies for CKM syndrome
  • Review key clinical trials of incretin therapies in chronic kidney disease, cardiovascular disease, heart failure, and additional metabolic risk factors

Description: 

GLP-1 receptor agonists have emerged as key therapies in cardiovascular-kidney-metabolic (CKM) syndrome, with benefits extending beyond weight loss and glycemic control. This session will review the evolving evidence supporting their use in obesity, cardiovascular disease, chronic kidney disease, and additional metabolic risk factors. Pharmacists and pharmacy technicians will gain practical insights into patient selection, guideline-directed therapy, and strategies to optimize care across the CKM disease continuum.


 

 
 


Members: FREE
Non-Members: $25.00


Date:Sunday, December 13
Time: 6:00 - 7:00PM

Accredited for Pharmacists and Technicians:
1.0 Hour of ACPE Continuing Education

 
 
 
 

2027 Planned Live Webinar Events

Details Coming Soon!

January - TBD
February - TBD